Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA has approved suzetrigine, a new, non-opioid medication for adults with moderate to severe acute pain.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...